Houston researches tap into GenAI for communicating genetic test results

hi, tech

Researchers at Baylor College of Medicine’s Human Genome Sequencing Center have trained an AI assistant to explain genetic test results to patients. Photo via Getty Images

Artificial intelligence in the health care setting has a lot of potential, and one Houston institution is looking into one particular use.

Researchers at Baylor College of Medicine’s Human Genome Sequencing Center have trained an AI assistant to explain genetic test results to patients. According to findings published in the Journal of the American Medical Informatics Association (JAMIA), the team has developed generative AI to understand and interpret genetic tests. They have also tested its accuracy against Open AI’s ChatGPT 3.5.

“We created a chatbot that can provide guidance on general pharmacogenomic testing, dosage implications, and the side effects of therapeutics, and address patient concerns,” explains first author Mullai Murugan in a press release. Murugan is director of software engineering and programming at the Human Genome Sequencing Center. “We see this tool as a superpowered assistant that can increase accessibility and help both physicians and patients answer questions about genetic test results.”

The initial chatbot training specifically targeted pharmacogenomic testing for statins, meaning a patient’s potential response to cholesterol-lowering drugs, as dictated by genetics.

Murugan explains why they decided to create their own chatbot in the key publication on statin pharmacogenomics was published in May 2022, four months after the training cutoff date for ChatGPT 3.5 in January 2022. Alternatively, her team’s technology uses Retrieval Augmented Generation (RAG) and was trained on the most recent guidelines.

How did the two AI assistants compare? Four experts on cardiology and pharmacogenomics rated both chatbots based on accuracy, relevancy, risk management, and language clarity, among other factors. Though the AI scored similarly on language clarity, Baylor’s chatbot scored 85 percent in accuracy and 81 percent in relevancy compared to ChatGPT’s 58 percent in accuracy and 62 percent in relevancy when asked questions from healthcare providers.

“We are working to fine-tune the chatbot to better respond to certain questions, and we want to get feedback from real patients,” Murugan says. “Based on this study, it is very clear that there is a lot of potential here.” Nonetheless, Murugan emphasized that there is much work still to be done before the program is ready for clinical applications. That includes training the chatbot to explain results in the language used by genetic counselors. Funds from the NIH’s All of Us Research Program helped to make the research possible.

From Your Site Articles
Houston-based alive5 has over 800 customers using their chatbox services — and has found a special niche in sports team's websites. Photo via alive5.com

Houston startup hopes to revolutionize the chatbot business

chatterboxes

It seems like every other webpage nowadays has a virtual assistant that pops up via a chat box. A Houston startups is hoping to ride the wave of this digital marketing initiative.

Houston-based alive5 has created a platform that allows small-to-medium-sized businesses to engage customers using Chatbot Technology, from their websites, apps, SMS text-message, and social media pages.

"What we do at alive5 is really simple," says Glenn Gutierrez, COO and co-founder of alive5. "We help your business make more conversations."

Gutierrez and his co-founder Dustin Yu started out in 2017 as Alive Chat System and they were one of the first chat systems in Texas.

"Our chat system was kind of a common system that you might see on a website that says, 'Hey, how can I help you today?" says Gutierrez. "And when you press that button, somebody on the other end sends a message and says, 'Hey, how are you doing today? How can I help you?"

After exploring how to take the company, which was initially a lifestyle product, to scale, they added new products and found new ways for their clients to have more conversations with their customers.

"We had to create as many channels as possible outside of web chat," says Gutierrez. "We talked about the live chat system, moving into SMS text message, moving into social media and interestingly enough, we started moving into business cards with QR codes where people can actually scan a QR code or text a phone number and we can automatically build a relationship with a customer at an event, in person or from a billboard.

"And that activates pretty much all the rest of the system for businesses to be able to engage a customer. So we think about ourselves as the best way to help you create more conversations, not just on your website, but pretty much anywhere you would engage a customer."

The platform enjoyed a meteoric rise in the chat space due to its participation in Capital Factory's accelerator program. From there, they were placed in another accelerator program in Philadelphia, the Comcast NBCUniversal LIFT Labs Accelerator, powered by Techstars.

"Because of the boost from the accelerator programs, we developed relationships with a lot of great organizations," says Gutierrez. "Today, we service over 800 customers, including 200 of the top college sports teams and pro teams like the NBA, NFL and NHL."

The platform's collaboration helps teams sell more tickets, especially premium seat tickets, by facilitating conversations with VIP clients and allowing fans the opportunity to go to the team's website to use the automated chat solution.

"A good example of one of those is the Jacksonville Jaguars website," says Gutierrez. "You can go there and see one of our chat boxes available to assist with inquiries or questions that you may have before, during or after a game. And our solution is built for organizations with a high volume of customer interactions to automate some of those tier one questions."

Alive5 also services customers like Royal Caribbean Cruise Line, major hotel brands and other companies in the hospitality space. They are also now collaborating with Spectra Venue Management, which manages hundreds of venues throughout North America, to pilot alive5's messaging and concierge services.

Outside of their inroads in the chat space, the platform is creating AI-powered strategies to help companies maximize their communication opportunities at personal touchpoint events such as conferences and trade shows.

"With our A.I. powered business cards, we're able to take an engagement that happens at a conference, an event or at a networking session and turn that into a prospect that's now part of a company's digital lead funnel," says Gutierrez. "What we're proposing is to give them a laser-etched metal business card with the QR code. That is better than just giving them a paper business card that they will take and may or may not call you and that's it, that's the end of the interaction.

"With the QR code, a potential contact can scan it and it will send them a demo of our product to their phone and it will give them all of a client's contact details so they can reach out to that client anytime they're ready to buy. The best part about that is that now you have something that no other system can do and you have that customer's phone number available to you at any point in time."

Moving forward, the Houston-based platform wants to do everything within its power to be one of the most successful chat companies nationwide.

"I like to think about our product like a Lego set," says Gutierrez. "It's up to you to choose what package you want. I've been in the startup space for a long time and to finally see that ecosystem starting to mature to the point that businesses are more open to digitally transforming their organizations, where they're understanding the need to take risks, to try new things, that's great for us.

"When you think about a company that can help you with your communication, I want alive5 to be the first company on their minds."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings